A5024089316- SARS-CoV-2 and COVID-19 Research
- Hematopoietic Stem Cell Transplantation
- CAR-T cell therapy research
- COVID-19 Clinical Research Studies
- Immune Cell Function and Interaction
- Viral gastroenteritis research and epidemiology
- Animal Virus Infections Studies
- Virus-based gene therapy research
- RNA Interference and Gene Delivery
- SARS-CoV-2 detection and testing
- Viral Infectious Diseases and Gene Expression in Insects
- Mesenchymal stem cell research
- Pulmonary Hypertension Research and Treatments
- Tissue Engineering and Regenerative Medicine
- Cardiovascular Function and Risk Factors
- Congenital Heart Disease Studies
- RNA Research and Splicing
- Acute Myeloid Leukemia Research
- Epigenetics and DNA Methylation
- Viral Infections and Immunology Research
- Long-Term Effects of COVID-19
- T-cell and B-cell Immunology
- RNA and protein synthesis mechanisms
- CRISPR and Genetic Engineering
- Prosthetics and Rehabilitation Robotics
Yeditepe University
2015-2023
Acıbadem Adana Hospital
2021-2023
Acıbadem University
2020-2022
Czech Academy of Sciences, Institute of Biotechnology
2022
Yeditepe University Hospital
2018
Background: c-Myc plays a major role in the maintenance of glycolytic metabolism and hematopoietic stem cell (HSC) quiescence. Objective: Targeting modulators HSC quiescence could lead to cycle entry with concomitant expansion. Methods Results: Here we show that inhibitor 10074-G5 treatment leads 2-fold increase murine LSKCD34low compartment post 7 days. In addition, inhibition increases CD34+ CD133+ human number. downregulation cyclindependent kinase (CDKI) gene expression ex vivo vivo....
Meis1, which belongs to TALE-type class of homeobox gene family, appeared as one the key regulators hematopoietic stem cell (HSC) self-renewal and a potential therapeutical target. However, small molecule inhibitors MEIS1 remained unknown. This led us develop that could modulate HSC activity. To this end, we have established library relevant family developed high-throughput in silico screening strategy against homeodomain MEIS proteins using AutoDock Vina PaDEL-ADV platform. We screened over...
Abstract COVID-19 outbreak caused by SARS-CoV-2 created an unprecedented health crisis since there is no vaccine for this novel virus. Therefore, vaccines have become crucial reducing morbidity and mortality. In study, in vitro vivo safety efficacy analyzes of lyophilized candidates inactivated gamma-irradiation were performed. The candidate study OZG-3861 version 1 (V1), virus vaccine, SK-01 a GM-CSF adjuvant added vaccine. applied intradermally to BALB/c mice assess toxicity...
Abstract The SARS-CoV-2 virus caused the most severe pandemic around world, and vaccine development for urgent use became a crucial issue. Inactivated formulated vaccines such as Hepatitis A smallpox proved to be reliable approaches immunization prolonged periods. In this study, gamma-irradiated inactivated does not require an extra purification process, unlike chemically vaccines. Hence, novelty of our candidate (OZG-38.61.3) is that it non-adjuvant added, gamma-irradiated, intradermally...
Relapsed and refractory CD19-positive B-cell acute lymphoblastic leukemia (ALL) non-Hodgkin lymphoma (NHL) are the focus of studies on hematological cancers. Treatment these malignancies has undergone recent transformation with development new gene therapy molecular biology techniques, which safer well-tolerated therapeutic approaches. The CD19 antigen is most studied target in This study reports results clinical-grade production, quality control, vivo efficacy processes ISIKOK-19 cells as...
microRNAs (miRs) are proposed as critical molecular targets in SARS-CoV-2 infection. Our recent silico studies identified seven specific miR-like sequences, which highly conserved with humans, including miR-1307-3p, roles COVID-19. In this current study, Vero cells were infected SARS-CoV-2, and miR expression profiles thereafter confirmed by qRT-PCR. miR-1307-3p was the most expressed cells; we, therefore, transiently inhibited its both uninfected cells. The...
Chimeric antigen receptor T (CAR-T) cell therapies have already made an impact on the treatment of B-cell malignancies. Although CAR-T are promising, there concerns about commercial products regarding their affordability and sustainability. In this preliminary study, results first production clinical data academic (ISIKOK-19) trial in Turkey presented.A pilot (NCT04206943) designed to assess safety feasibility ISIKOK-19 T-cell therapy for patients with relapsed refractory CD19+ tumors was...
Hemophilia A is an X-linked recessive bleeding disorder caused by a deficiency of plasma coagulation factor VIII (FVIII), and it accounts for about 80%-85% all cases hemophilia. Plasma-derived therapies or recombinant FVIII concentrates are used to prevent treat the symptoms along with FVIII-mimicking antibodies. Recently, European Medicines Agency granted conditional marketing approval first gene therapy hemophilia A. The aim this study was determine effectiveness in correcting...
Duchenne Muscular Dystrophy (DMD) results in a deficiency of dystrophin expression patient muscle fibers, leading to progressive degeneration. Treatment DMD has undertaken current transformation with the advancement novel gene therapy and molecular biology techniques, which are secure, well-tolerated, effective therapeutic approaches.DMD therapies have mainly focused on young patients as vivo animal model trials been performed 0-1-month mice. However, it not yet answered how micro-dystrophin...
Hematopoietic stem cells (HSCs), which are multipotent and have the ability to self-renew, frequently used in treatment of hematological diseases cancer. Small molecules that target HSC quiescence regulators could be for ex vivo expansion both mobilized peripheral blood (mPB) umbilical cord (UCB) hematopoietic progenitor (HSPC). We identified investigated 35 small factors. looked at how they affected activity, such as expansion, quiescence, multilineage capacity, cycling ability, metabolism,...
Abstract COVID-19 outbreak caused by SARS-CoV-2 created an unprecedented health crisis since there is no vaccine for this novel virus. Therefore, vaccines have become crucial reducing morbidity and mortality. In study, in vitro vivo safety efficacy analyzes of lyophilized candidates inactivated gamma-irradiation were performed. The candidate study OZG-3861 version 1 (V1), virus vaccine, SK-01 a GM-CSF adjuvant added vaccine. applied intradermally to BALB/c mice assess toxicity...
Abstract The SARS-CoV-2 virus caused the most severe pandemic around world, and vaccine development for urgent use became a crucial issue. Inactivated formulated vaccines such as Hepatitis A, oral polio vaccine, smallpox proved to be reliable approaches immunization prolonged periods. During pandemic, we produced an inactivated candidate, having advantages of being manufactured rapidly tested easily in comparison with recombinant vaccines. In this study, that includes gamma irradiation...
Abstract Meis1 , which belongs to TALE-type class of homeobox gene family, appeared as one the key regulators hematopoietic stem cell (HSC) self-renewal and a potential therapeutical target. However, small molecule inhibitors MEIS1 remained unknown. This led us develop that could modulate HSC activity. To this end, we have established library relevant family developed high-throughput in silico screening strategy against homeodomain MEIS proteins using AutoDock Vina PaDEL-ADV platform. We...
c-Myc plays a major role in the maintenance of glycolytic metabolism and hematopoietic stem cell (HSC) quiescence. Targeting modulators HSC quiescence could lead to cycle entry with concomitant expansion. Here we show that inhibitor 10074-G5 treatment leads 2-fold increase murine LSKCD34low compartment post 7 days. In addition, inhibition increases CD34+ CD133+ human number. downregulation cyclin-dependent kinase (CDKI) gene expression ex vivo vivo. upregulates HDR modulator Rad51 cells....
Abstract BACKGROUNDThe efficacy of SARS-CoV2 single donor convalescent plasma (CP) varied according to the application time and amount antibody that is administered. Single CP has some drawbacks; such as insufficient levels neutralizing activities, requirements blood group compatibility, risk infection transmission. In this study, safety pathogen inactivated, isohemagglutinin-depleted (concentrated) pooled product was investigated. MATERIALS AND METHODSA total sixteen patients were treated...
Abstract BACKGROUND The efficacy of SARS-CoV2 single donor convalescent plasma (CP) varied according to the application time and amount antibody that is administered. Single CP has some drawbacks; such as insufficient levels neutralizing activities, requirements blood group compatibility, risk infection transmission. In this study, safety pathogen inactivated, isohemagglutinin-depleted (concentrated) pooled product was investigated. METHODS A total sixteen patients were treated with either...
ABSTRACT In recent times, chimeric antigen receptor (CAR)-T cell therapy has shown rapid advancements and gained clinical approval for use in cancer immunotherapy. CAR, a synthetic integrated into autologous T cells, yielded highly successful results patients with leukemia. The significant potential of CAR-T cells been validated through trials adult pediatric treatments. Our developed specifically CD19-specific Acute Lymphoblastic Leukemia (ALL) promising vitro vivo tests. To enhance the...
Abstract BACKGROUND The efficacy of SARS-CoV2 single donor convalescent plasma (CP) varied according to the application time and amount antibody that is administered. Single CP has some drawbacks; such as insufficient levels neutralizing activities, requirements blood group compatibility, risk infection transmission. In this study, safety pathogen inactivated, isohemagglutinin-depleted (concentrated) pooled product was investigated. METHODS A total sixteen patients were treated with either...
Abstract Hematopoietic stem cells (HSC), known for their ability to multipotent and self-renew, are often used in HSC transplantation the treatment of hematological diseases malignancies. Umbilical cord blood (UCB) mobilized peripheral (mPB), which alternatives bone marrow (BM) transplantation, have reduced HSC. To address this restriction, ex vivo expansion HSCs is a highly promising therapeutic approach rather than use double-cord unit that induces delays hematopoietic recovery. We...
Abstract Objective Chimeric antigen receptor T (CAR-T) cell therapies already made an impact on the treatment of B malignancies. Although CAR-T are promising, there concerns with commercial products regarding their affordability and sustainability. In this preliminary study, results first productional clinical data academic (ISIKOK-19) from Turkey presented. Materials Methods A pilot trial ( NCT04206943 ) designed to assess safety feasibility ISIKOK-19 T-cell therapy in patients relapsed...